What Makes Biomea Fusion, Inc. (BMEA) a Good Fit for 'Trend Investing'Zacks Investment Research • 03/20/23
Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes in the United States in Ongoing Phase I/II (COVALENT-111) Study of BMF-219GlobeNewsWire • 01/04/23
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent Menin Inhibitor BMF-219 in Type 2 DiabetesGlobeNewsWire • 12/14/22
Biomea Fusion Presents at the 2022 ASH Annual Meeting Preclinical Data on BMF-500 Supporting its Potential as the Most Potent and Selective FLT3 Inhibitor to DateGlobeNewsWire • 12/12/22
Biomea Fusion to Participate in Piper Sandler 34th Annual Healthcare ConferenceGlobeNewsWire • 11/11/22
Biomea Fusion Reports Third Quarter 2022 Financial Results and Business HighlightsGlobeNewsWire • 11/07/22
Biomea Fusion to Present Preclinical Data for BMF-500, an Investigational Oral Covalent FLT3 Inhibitor, at the 64th American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 11/03/22
Biomea Fusion Presents New Translational Data at the European Association for the Study of Diabetes (EASD) 2022 in Animal Models and Ex-vivo Human Donor Islets Further Supporting BMF-219's Potential as an Oral, Long-Acting Treatment for Type 2 DiabetesGlobeNewsWire • 09/22/22
Biomea Fusion Presents New Preclinical Data at the European Association for the Study of Diabetes (EASD) Annual Meeting Describing BMF-219's Potential as a Novel, Oral, Long-Acting Treatment for Type 2 DiabetesGlobeNewsWire • 09/20/22
Biomea Fusion Presents Additional Preclinical Data Demonstrating Anti-Tumor Activity and Mechanistic Evidence for BMF-219 in Diffuse Large B-Cell Lymphoma and Multiple Myeloma Models at International Myeloma Society Annual MeetingGlobeNewsWire • 08/26/22
Biomea Fusion Reports Second Quarter 2022 Financial Results and Business HighlightsGlobeNewsWire • 08/01/22
Biomea Fusion Selected for Two Oral Presentations at the European Association for the Study of Diabetes Annual Meeting Describing BMF-219's Potential as a Novel, Oral, Long-Acting, Acute Treatment for Type 2 DiabetesGlobeNewsWire • 07/01/22
Biomea Fusion Announces First Patient Dosed in Multiple Myeloma Cohort of COVALENT-101 TrialGlobeNewsWire • 06/22/22
Biomea Fusion Presents Novel Preclinical Data at ADA 2022 Suggesting BMF-219's Potential as an Oral, Long-Acting Treatment for Type 2 DiabetesGlobeNewsWire • 06/04/22
Biomea Fusion to Present New Preclinical Data Showing BMF-219's Strong Activity in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Tumor Models at ASCO 2022GlobeNewsWire • 05/26/22
Biomea Fusion Reports First Quarter 2022 Financial Results and Business HighlightsGlobeNewsWire • 05/16/22
Biomea Fusion to Participate in Bank of America Securities 2022 Healthcare ConferenceGlobeNewsWire • 05/09/22
Biomea Fusion Announces Acceptance of Multiple Abstracts at the 2022 ASCO Annual MeetingGlobeNewsWire • 04/27/22
Biomea Fusion Reports Preclinical Data on BMF-219 and Trial in Progress Presentations at AACR 2022 Annual MeetingGlobeNewsWire • 04/08/22